Pharmaceuticals, Biotechnology and Life Sciences
Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough…
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) (“COSCIENS”…
– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024;…
Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024CARSON CITY, Nev., Aug. 06, 2024 (GLOBE…
Company to Also Participate in 2024 Wedbush PacGrow Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) — Fennec…
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused…
Company announcement no. 6 – 24 2 August 2024 NTG Nordic Transport Group acquires SCHMALZ+SCHÖN Holding GmbH NTG Germany GmbH…
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a…
/Not for distribution to U.S. news wire services or for dissemination in the United States/ VANCOUVER, British Columbia, Aug. 02,…
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and…